Pharmaceuticals in Brazil Current Behavior Changes Analysis

Ongoing Behavior Changes

Analysis of the provided reports on Final Customers Identification and Current Demand Behavior reveals several ongoing behavior changes impacting relationships and demand within the Brazilian pharmaceutical value chain, particularly evidenced in data from 2024.

A significant and observable change is the growing demand from individual consumers, reflected directly in the increasing retail sales volume. In 2024, the retail pharmaceutical market commercialized 8.1 billion units, a 6.1% increase compared to the 7.6 billion units sold in 2023. This rise in volume suggests a growing number of individual transactions and potentially higher per capita consumption, driven in part by factors such as an aging population and increased access to healthcare. This growing demand translates into higher purchasing volumes from retail pharmacies (B2B customers of distributors/manufacturers) and necessitates increased production and distribution flows.

Another notable change is the evolving role and behavior of retail pharmacies, particularly the large chains. There is significant consolidation occurring, with the top three pharmacy chain groups (RD Saúde, Grupo DPSP, Grupo Pague Menos) concentrating approximately 40% of the main consumer market share among chains. These large networks are not only expanding their physical footprint – with an average of 22 new pharmacies opening daily in 2024 – but are also increasingly adopting a "health hub" model. This involves expanding their offerings beyond just dispensing medicines to include a wider range of non-pharmaceutical products and convenient health services such as vaccination and basic health checks. This behavioral shift by retail pharmacies impacts their purchasing patterns (increasing demand for a diverse product mix) and their competitive strategies, putting pressure on smaller, independent pharmacies.

Furthermore, there is a strong and expressed consumer preference for increased domestic production of medicines and pharmaceutical inputs. A significant 90% of Brazilians favor boosting national production. While this is a sentiment rather than a direct purchasing behavior change, it reflects a growing awareness and desire for greater national self-sufficiency in the pharmaceutical sector. This sentiment can influence government policies and potentially shift relationships within the value chain by encouraging investment in domestic API production.

The Public Health System (SUS) continues to be a major demand driver, acting as a significant B2G customer. While its fundamental purchasing behavior (via tenders and procurement) remains consistent, the increasing overall market size and public health needs ensure that SUS procurement volumes remain substantial and critical for manufacturers and distributors supplying this segment.

In summary, the key ongoing behavior changes identified are the quantifiable increase in individual consumer demand (volume), the strategic evolution and consolidation of retail pharmacies towards a "health hub" model, and a strong consumer preference for domestic production, alongside the sustained, large-scale demand from the government via the SUS.

Here is a table summarizing the impact of these changes on the value chain:

Value Chain Step	Impact of Behavior Changes
Input Production	Increased overall demand (driven by retail growth) requires higher input volumes. Strong consumer preference for domestic production creates pressure/opportunity for growth in national API production, potentially shifting reliance away from international suppliers over time.
Pharmaceutical Production	Higher demand necessitates increased manufacturing output. The growing generics/similars market (reflecting affordability needs) remains crucial. The retail shift towards health hubs may influence demand for a broader product portfolio from manufacturers. Sustained B2G demand requires dedicated production/supply for the SUS.
Distribution	Increased volume requires more efficient logistics, warehousing, and transportation capacity. The expansion of retail chains necessitates broader distribution reach. Consolidation in retail shifts power dynamics, potentially leading to larger order volumes but also greater negotiation pressure from major retail groups. Continued need for cold chain and traceability compliance.
Retail & Commercialization	Directly benefits from increased individual consumer demand (volume). Faces intense competition, especially from large chains expanding their footprint and service offerings ("health hubs"). Independent pharmacies face pressure from chain consolidation. Relationship with consumers evolves as pharmacies become broader health destinations. B2B relationship with distributors/manufacturers is influenced by chain purchasing power.

References

Abradilan. Dez maiores farmacêuticas do Brasil detêm 48,6% das vendas. Abradilan. Dez maiores farmacêuticas detêm 48,6% das vendas. Abradilan. Crescimento das grandes redes de farmácias. Abradilan. Setor farmacêutico cresce 12,7% em 2024, mas reajuste autorizado gera dúvidas e impacto no bolso do consumidor. Agência Gov. Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos. Anvisa. Anvisa divulga dados do anuário sobre a indústria farmacêutica no Brasil. BNDES. Cadeia farmacêutica no Brasil: avaliação preliminar e perspectivas. CNN Brasil. Brasil importa 90% da matéria-prima para a produção de medicamentos. Dr. Fisiologia. Indústria farmacêutica brasileira e suas tendências (2025). Febrafar. Varejo farmacêutico: veja destaques de 2024 e expectativas para 2025. FIA. Indústria farmacêutica: características, setores e mercado de trabalho. ICTQ. Os modelos de negócios farmacêuticos. InvesteSP. Setor farmacêutico é o que mais investe em pesquisa e desenvolvimento. MOOC Fiocruz. Indústria Farmacêutica no Brasil: um breve panorama. Medicina SA. 90% dos brasileiros preferem a produção de medicamentos e insumos no país. Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. Medicina SA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bilhões em 2024. Natcofarma. Varejo farmacêutico: Confira as principais tendências. Omni Hospitalar. Como funciona o processo de distribuição de medicamentos?. VEJA. 90% dos brasileiros dizem que produção nacional de remédios deve aumentar. VEJA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bi em 2024.